URL copied to clipboard

Trending News

Suraksha Diagnostic IPO Sees Growing Interest with 0.25x Subscription on Day 2 – Learn More!

Suraksha Diagnostic IPO was subscribed 0.25 times on Day 2, with 0.00x QIBs, NIIs at 0.13x, and RIIs at 0.45 times subscription.
Suraksha Diagnostic IPO Subscribed 0.25x on Day 2, with Varied Interest Across Investor Categories!
Suraksha Diagnostic IPO Subscribed 0.25x on Day 2, with Varied Interest Across Investor Categories!

Suraksha Diagnostic Limited IPO saw a 0.25x subscription on Day 2, with QIBs at 0.00x, NIIs at 0.13x, and RIIs at 0.45x. The subscription patterns indicate varied levels of investor interest, with retail investors showing more enthusiasm compared to institutional buyers.

Alice Blue Image

Suraksha Diagnostic Limited IPO Subscription Status

Suraksha Diagnostic IPO saw mixed interest on opening day with a 0.11x subscription, reflecting positive market sentiment and investor optimism about the company’s growth potential.

How to check Suraksha Diagnostic Ltd IPO Subscription Status?

Steps to check Suraksha Diagnostic Ltd IPO subscription status on NSE

Following are the steps to check it through the NSE website

  • Visit NSE‘s official website.
  • Navigate to the ‘Market Data’ tab.
  • Choose ‘IPO’.
  • Select the ‘Suraksha Diagnostic Ltd IPO’ to check its subscription status.
  • Opt for either NSE Bid details or Consolidated Bid details.
  • Explore the total number of bids received from various investors. 

Suraksha Diagnostic Ltd IPO Allotment Status

The allotment date for the Suraksha Diagnostic Ltd IPO is set for December 4, with shares priced from ₹420 to ₹441 per share and a face value of ₹2. The offering consists of lots of 34 shares, with bids accepted for these lots or their multiples.

Alice Blue Image

Suraksha Diagnostic Ltd IPO Listing Date 

Suraksha Diagnostic Ltd IPO is expected to be listed on the NSE SME on December 6, 2024.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.

Loading
Read More News